Alkermes Exclusivity Extension for Lybalvi Offsets Alixorexton Pricing Adjustment, RBC Says

MT Newswires Live11-14

Alkermes' (ALKS) settlement with Teva Pharmaceuticals (TEVA) regarding a generic Lybalvi largely offsets downward pricing adjustments for alixorexton following competitor pricing, RBC Capital Markets said in a Thursday note.

Under the settlement, Teva is barred from launching its generic version until November 2039, or May 2040 under certain circumstances, removing prior modeled assumptions of generic competition starting in 2032.

RBC updated its model to reflect continued Lybalvi revenues through 2035 with peak sales expected at $722 million, compared with its prior guidance of $213 million.

Concurrently, following Takeda Pharmaceutical's (TAK) orexin pricing announcement of $16,500 per month across all three doses, for an annualized list price of $198,000, RBC lowered its expected price for alixorexton to about $288,000 annually from $350,000.

The firm now models 2035 alixorexton sales of $2.7 billion, down from its earlier expectation of $3.3 billion.

RBC Capital Markets maintained its outperform rating on Alkermes and a $57 price target.

Price: 46.67, Change: -0.31, Percent Change: -0.66

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment